GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » Financial Strength
中文

ObsEva (ObsEva) Financial Strength

: 0 (As of Dec. 2022)
View and export this data going back to 2017. Start your Free Trial

ObsEva has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

ObsEva's Interest Coverage for the quarter that ended in Dec. 2022 was 1.59. ObsEva's debt to revenue ratio for the quarter that ended in Dec. 2022 was 0.04. As of today, ObsEva's Altman Z-Score is 0.00.


Competitive Comparison

For the Biotechnology subindustry, ObsEva's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, ObsEva's Financial Strength distribution charts can be found below:

* The bar in red indicates where ObsEva's Financial Strength falls into.



ObsEva Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

ObsEva's Interest Expense for the months ended in Dec. 2022 was $-4.76 Mil. Its Operating Income for the months ended in Dec. 2022 was $7.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil.

ObsEva's Interest Coverage for the quarter that ended in Dec. 2022 is

Interest Coverage=-1*Operating Income (Q: Dec. 2022 )/Interest Expense (Q: Dec. 2022 )
=-1*7.566/-4.756
=1.59

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

ObsEva's Debt to Revenue Ratio for the quarter that ended in Dec. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.027 + 0) / 78.548
=0.04

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

ObsEva has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ObsEva  (GREY:OBSEF) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

ObsEva has the Financial Strength Rank of 0.


ObsEva Financial Strength Related Terms

Thank you for viewing the detailed overview of ObsEva's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (ObsEva) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
Executives
William Michael Brown officer: Chief Financial Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan director, officer: Chief Executive Officer 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye director C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228

ObsEva (ObsEva) Headlines

From GuruFocus

ObsEva Receives Nasdaq Non-Compliance Notice

By PurpleRose PurpleRose 08-22-2022